Abbisko Raises $226 Million in Hong Kong IPO for Cancer Therapies
October 15, 2021 at 05:52 AM EDT
Abbisko, a Shanghai biopharma, completed a $226 million IPO in Hong Kong to support its small molecule therapies for cancer. At the IPO price, Abbisko has a $1.1 billion market capitalization. Formed in 2016, Abbisko has developed a portfolio of 14 drug candidates, five of them at clinical stage. Its lead program, a pan-FGFR inhibitor aimed at urothelial carcinoma, is partnered with AstraZeneca. The company plans to start Phase Ib/II China trials for the candidate soon. More details.... Stock Symbol: (HK: 2256) Share this with colleagues: // //
